IRIS UniCatt

Metafuni, Elisabetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.425
AS - Asia 3.011
EU - Europa 2.606
SA - Sud America 584
AF - Africa 92
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.725
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.314
SG - Singapore 1.407
CN - Cina 734
DE - Germania 625
IT - Italia 512
BR - Brasile 469
SE - Svezia 453
FR - Francia 291
VN - Vietnam 258
GB - Regno Unito 163
IE - Irlanda 125
IN - India 120
FI - Finlandia 101
ID - Indonesia 89
UA - Ucraina 76
JP - Giappone 75
RU - Federazione Russa 65
HK - Hong Kong 55
CA - Canada 53
BD - Bangladesh 47
KR - Corea 46
MX - Messico 37
AR - Argentina 36
NL - Olanda 36
IQ - Iraq 31
PL - Polonia 30
TR - Turchia 29
ZA - Sudafrica 25
AT - Austria 24
BE - Belgio 21
CI - Costa d'Avorio 21
CO - Colombia 20
SA - Arabia Saudita 19
CZ - Repubblica Ceca 16
EC - Ecuador 15
ES - Italia 14
CL - Cile 11
MA - Marocco 11
UZ - Uzbekistan 11
VE - Venezuela 11
KE - Kenya 9
PK - Pakistan 9
UY - Uruguay 9
PH - Filippine 8
TH - Thailandia 8
DZ - Algeria 7
JO - Giordania 7
PY - Paraguay 7
SN - Senegal 7
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
IL - Israele 6
JM - Giamaica 6
NP - Nepal 6
RO - Romania 6
LT - Lituania 5
PT - Portogallo 5
AM - Armenia 4
AU - Australia 4
AZ - Azerbaigian 4
BG - Bulgaria 4
EG - Egitto 4
IR - Iran 4
LV - Lettonia 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
AL - Albania 3
CR - Costa Rica 3
KZ - Kazakistan 3
LB - Libano 3
PE - Perù 3
QA - Qatar 3
AO - Angola 2
BH - Bahrain 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
GR - Grecia 2
GY - Guiana 2
HU - Ungheria 2
KG - Kirghizistan 2
LI - Liechtenstein 2
MD - Moldavia 2
MY - Malesia 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
EU - Europa 1
GE - Georgia 1
HN - Honduras 1
HR - Croazia 1
IS - Islanda 1
KI - Kiribati 1
Totale 9.715
Salva come PNG Salva come JPEG
Città #
Singapore 790
Chandler 402
San Jose 378
Ashburn 329
Beijing 148
Dublin 123
Hefei 122
Rome 115
Los Angeles 106
New York 97
Lauterbourg 85
Jakarta 82
Munich 81
Ho Chi Minh City 79
Milan 78
Frankfurt am Main 76
Tokyo 74
Dallas 73
Hanoi 71
San Mateo 68
The Dalles 65
Chicago 63
Jacksonville 62
Houston 61
Hyderabad 53
Florence 49
Hong Kong 49
Nanjing 49
Council Bluffs 48
Dearborn 48
Helsinki 46
São Paulo 46
Seoul 44
Marseille 43
Ann Arbor 42
Santa Clara 39
Wilmington 38
Moscow 37
Boston 36
Kent 36
Lancaster 34
Princeton 33
Buffalo 31
Cattolica 30
Nürnberg 29
Boardman 28
Seattle 28
London 27
Bremen 26
Nuremberg 26
Orem 26
Lappeenranta 25
Nanchang 22
Abidjan 21
Brussels 21
Toronto 21
Warsaw 21
Atlanta 19
Rio de Janeiro 19
Tianjin 19
Guangzhou 18
Shanghai 18
Paris 17
Stockholm 17
Brooklyn 16
Denver 16
Johannesburg 16
Poplar 16
Tukwila 16
Belo Horizonte 15
Izmir 15
Phoenix 15
Washington 15
Woodbridge 15
Amsterdam 14
Turku 14
Fairfield 13
Lawrence 13
Montreal 13
Pune 13
Augusta 12
Brno 12
Curitiba 12
Naples 12
Vienna 12
Baghdad 11
Da Nang 11
Dhaka 11
Haiphong 11
Mexico City 11
Norwalk 11
Portsmouth 11
San Francisco 11
Düsseldorf 10
Redwood City 10
Tashkent 10
Bexley 9
Brasília 9
Campinas 9
Charlotte 9
Totale 5.356
Salva come PNG Salva come JPEG
Nome #
Salivary proteomic analysis and acute graft versus host disease after allogeneic hematopoietic stem cell transplantation 230
Correlation between paraproteinaemia and viral reactivation after allo-SCT 216
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation. 188
The role of HLA--G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis 181
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 177
Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia 169
Hyperleukocytosis and leukostasis: management of a medical emergency 162
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation 159
Cytokine profile of autologous platelet-derived eye drops in patients with ocular chronic graft-versus-host disease 159
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 158
The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue 151
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 151
MTHFR polymorphisms and vitamin B12 deficiency: correlation between mthfr polymorphisms and clinical and laboratory findings 148
H1N1 Influenza among Hematological Patients: Monocentric Influenza Cases from 2011 to 2016 147
Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B-cell acute lymphoblastic leukemia 147
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 146
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 146
Role of fecal calprotectin as biomarker of gastrointestinal GVHD after allogeneic stem cell transplantation 139
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T 138
Fecal but not serum calprotectin is a potential marker of GVHD after stem cell transplantation. 137
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 134
Cytokine profile of autologous platelet-derived eye drops in patients with ocular chronic graft-versus-host disease 132
Inline and offline extracorporeal photopheresis: Device performance, cell yields and clinical response 132
Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal 132
Unselected donor-derived hematopoietic stem cells boost for Chimeric Antigen Receptor T-cell associated hematotoxicity 129
Allogeneic hematopoietic stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult: Monocentric observational study and review of the literature 129
Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B-cell acute lymphoblastic leukemia 126
Pure red cell aplasia among ABO mismatched hematopoietic stem cell transplant recipients: a 13-years retrospective study and literature review 123
Donor cell-derived myelofibrosis relapse after allogeneic stem cell transplantation 122
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells 122
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid 121
Successful "on- demand" plerixafor for autologous peripheral blood stem-cells transplantation for relapsed/refractory germ cell tumors. 121
UGT1A1 Polymorphism and Mortality Outcome after Allogeneic Stem Cell Transplantation with Busulfan Based Regimen 118
Changes in protein serum levels during stem cell transplantation 115
Unrelated cord blood transplantation and post-transplant cyclophosphamide 115
Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes? 115
Acute graft versus host disease 1976-2020: reduced incidence and predictive factors 113
Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience 113
Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 y with Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study 112
Cytokine profile of autologous platelet-derived eye drops in patients with ocular chronic graft-versus-host disease 112
Effect of HLA mismatch on post-transplant infections in allogeneic hematopoietic stem cell transplantation with PTCy-based GvHD prophylaxis 111
Increased CD95 (Fas) and PD-1 expression in peripheral blood T lymphocytes in COVID-19 patients 111
Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir-exposed CMV-free population receiving PTCy 111
ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- And Long-term Outcomes 110
Bone marrow haploidentical transplant with post-transplantation cyclophosphamide :does graft cell content have an impact on main clinical outcomes? 108
Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients 107
Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML 107
Discrepancy between recipient and donor rs4364254 heparanase single nucleotide polymorphism impacts graft-versus-host disease after allogeneic stem cell transplant 107
CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation 107
Haploidentical bone marrow transplantation for AML in remission following TBF conditioning: a long-term follow up 107
The impact of donor-specific antibodies’ presence on the outcome post-allogeneic hematopoietic stem cell transplantation: a survey from a single center 106
Peripheral Blood Allogeneic Stem Cell Mobilization: Can We Predict a Suboptimal Mobilization? 105
Post-transplant cyclophosphamide with Sirolimus or Cyclosporine for GvHD prophylaxis in matched related and unrelated transplantation: a two-center analysis on 213 consecutive patients 104
Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. 102
Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion 101
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study 101
Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML 98
Impact of SARS-CoV-2 vaccination and passive prophylaxis with tixagevimab/cilgavimab on CAR-T patients: a three-year regional experience from the Italian covid pandemic 97
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 97
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 96
Unrelated cord blood transplantation and post-transplant cyclophosphamide 96
Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current management 91
Impact of Covid 19 pandemic on hematopoietic stem cell transplantation activities: Report from a single center 91
full donor chimerism after allogenic hematopoietic stem cells transplant for myelofibrosis the role of the conditioning regiment 91
Days alive outside hospital and readmissions in patients undergoing allogeneic transplants from identical siblings or alternative donors 91
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 90
The BLIND study: blinatumomab and DLI approach for management of B-ALL relapse after allogeneic stem cell transplantation. A multicentric Italian experience 90
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review 90
Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation 84
Second haploidentical stem cell transplantation for primary graft failure 83
Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML 82
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey 81
Late HBV reactivation after hematopoietic stem cell transplantation, despite long-term prophylaxis 81
The Role of Fecal Microbiota Transplantation in the Allogeneic Stem Cell Transplant Setting 79
Reducing infectious complications after allogeneic stem cell transplant 78
The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation 76
Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants 76
Four cases of transfusion-transmitted Hepatitis E virus infection: Is it time to introduce donor screening in Italy? 73
Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience 71
Hemorrhagic cystitis in allogeneic stem cell transplantation: a role for age and prostatic hyperplasia 70
Cord blood resilience in a patient with relapsing Ph + B lymphoblastic acute leukemia after hematopoietic stem cell transplantation 68
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review 66
Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant 62
Extending long term follow up of patient with acute myeloid leukemia after autologous stem cell transplantation: Disclosing late mortality and causes of death 62
The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation 56
Is Allogeneic Transplantation an Option in Patients Affected by Concurrent Myelofibrosis and Chronic Myeloid Leukemia (CML)? 52
Saprochaete clavata infection in immunosuppressed patients: Systematic review of cases and report of the first oral manifestation, focusing on differential diagnosis 32
Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion 30
CD19 expression on bone marrow hematogones and blasts following anti-CD19 therapy in B-ALL: a descriptive single-center analysis 10
Feasibility of allogeneic stem cell transplantation (HSCT) in patients with acute myeloid leukemia previously treated with CPX-351: report from a single center 4
Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation 4
Determinants of survival in patients treated with CPX-351 for acute myeloid leukemia 2
Totale 9.890
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.501
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.501
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217 0 0 0 0 0 0 0 0 0 0 0 7
2021/2022488 34 14 29 24 43 12 9 72 19 45 98 89
2022/20231.216 188 159 72 185 85 135 88 84 102 51 54 13
2023/2024776 29 156 45 60 21 94 65 43 17 56 85 105
2024/20251.997 47 52 127 101 170 65 89 85 215 218 472 356
2025/20264.168 616 146 319 471 627 231 650 229 324 278 172 105
Totale 9.890